Literature DB >> 18080035

Biological agents targeting interleukin-18.

Marija Jelusic1, Ivan Kresimir Lukic, Drago Batinic.   

Abstract

Interleukin (IL)-18 is an important regulator of both innate and acquired immune responses. It is upregulated in several human autoimmune and inflammatory diseases, and, therefore, might represent a novel therapeutic target. This review highlights the biology of IL-18, its central role in inflammation and immune response, as well as provides evidence for the involvement of IL-18 in selected chronic inflammatory diseases. After that, the authors discuss various therapeutic strategies of IL-18 blockade in clinical and preclinical models, particularly the inhibition of IL-18 secretion, IL-18 binding protein, anti-IL-18 monoclonal antibodies and soluble IL-18 receptor. (c) 2007 Prous Science. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18080035     DOI: 10.1358/dnp.2007.20.8.1157617

Source DB:  PubMed          Journal:  Drug News Perspect        ISSN: 0214-0934


  3 in total

Review 1.  Monoclonal Antibodies for Systemic Lupus Erythematosus (SLE).

Authors:  Claudio Ponticelli; Gabriella Moroni
Journal:  Pharmaceuticals (Basel)       Date:  2010-01-20

2.  Evaluation of exposure to secondhand smoke and serum level of interleukin 18 in non-smokers.

Authors:  Alireza Azargoon; Ali Kharazmkia; Nazanin Kordalivand; Mehdi Birjandi; Samareh Mir
Journal:  Ann Med Surg (Lond)       Date:  2022-01-03

Review 3.  Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: Biological role in induction, regulation, and treatment.

Authors:  Stella Amarachi Ihim; Sharafudeen Dahiru Abubakar; Zeineb Zian; Takanori Sasaki; Mohammad Saffarioun; Shayan Maleknia; Gholamreza Azizi
Journal:  Front Immunol       Date:  2022-08-11       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.